Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis

Simple item page
dc.contributor.authorLeukes, Vinzeigh N.en_ZA
dc.contributor.authorDorhoi, Ancaen_ZA
dc.contributor.authorMalherbe, Stephanus T.en_ZA
dc.contributor.authorMaasdorp, Eliznaen_ZA
dc.contributor.authorKhoury, Justineen_ZA
dc.contributor.authorMcAnda, Shirleyen_ZA
dc.contributor.authorWalzl, Gerharden_ZA
dc.contributor.authorDu Plessis, Nelitaen_ZA
dc.date.accessioned2023-05-11T12:24:46Zen_ZA
dc.date.available2023-05-11T12:24:46Zen_ZA
dc.date.issued2021-06en_ZA
dc.descriptionCITATION: Leukes, V. N. 'et al. 2021. Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis. Cellular Immunology 364(2021):12 pages. doi.10.1016/j.cellimm.2021.104359en_ZA
dc.descriptionThe original publication is available at: sciencedirect.comen_ZA
dc.description.abstractConventional anti-tuberculosis (TB) therapies comprise lengthy antibiotic treatment regimens, exacerbated by multi-drug resistant and extensively drug resistant mycobacterial strains. We assessed the ability of all-trans retinoic acid (ATRA), as repurposed compound serving as host-directed therapy (HDT), to counteract the suppressive effects of myeloid-derived suppressor cells (MDSCs) obtained from active TB cases (untreated or during week one of treatment) on T-cell responsiveness. We show for the first time that MDSCs suppress non-specific T-cell activation and production of interleukin (IL)-2, IL-4, IL-13 and GM-CSF via contact-dependent mechanisms. ATRA treatment decreases MDSC frequency, but fails to mature MDSCs to non-suppressive, terminally differentiated myeloid cells and does not restore T-cell function or cytokine production in the presence of MDSCs. The impact of ATRA treatment on improved immunity, using the concentration tested here, is likely to be minimal, but further identification and development of MDSC-targeting TB host-directed therapies are warranted.en_ZA
dc.description.versionPublisher’s versionen_ZA
dc.format.extent12 pagesen_ZA
dc.identifier.citationLeukes, V. N. 'et al. 2021. Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis. Cellular Immunology 364(2021):12 pages. doi.10.1016/j.cellimm.2021.104359en_ZA
dc.identifier.issn0008-8749 (online)en_ZA
dc.identifier.otherdoi.10.1016/j.cellimm.2021.104359en_ZA
dc.identifier.urihttp://hdl.handle.net/10019.1/126901en_ZA
dc.language.isoen_ZAen_ZA
dc.publisherElsevier Inc.en_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectMycobacterium tuberculosisen_ZA
dc.subjectMultidrug resistanceen_ZA
dc.subjectSuppressor cellsen_ZA
dc.subjectAntitubercular agentsen_ZA
dc.titleTargeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosisen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vinzeigh_targeting_2021.pdf
Size:
1.91 MB
Format:
Adobe Portable Document Format
Description:
download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Masters Degrees (Molecular Biology and Human Genetics)